Watch: The House Approved H.R. 3, The Pelosi Drug Bill. What Does That Mean?
KHN's Emmarie Huetteman appeared on PBS NewsHour to discuss efforts on Capitol Hill to curb the cost of prescription drugs.
Drug Costs
301 - 320 of 702 Results
-
-
KHN’s ‘What The Health?’: Legislate-A-Palooza
The House passed legislation that would give federal workers 12 weeks of paid parental leave. The measure appears headed for passage in the Senate, and President Donald Trump has promised to sign the measure into law. Meanwhile, House and Senate lawmakers have a tentative deal on surprise medical bills, but don’t count on a compromise just yet. Joanne Kenen of Politico, Kimberly Leonard of the Washington Examiner and Emmarie Huetteman of Kaiser Health News join guest host Mary Agnes Carey of KHN to discuss this and more. And for “extra credit,” the panelists offer their favorite health stories of the week they think you should read, too.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
-
KHN’s ‘What The Health?’: We Spend HOW MUCH On Health Care?
The annual accounting of national health spending is out. And the 2018 health bill for the U.S. was $3.6 trillion, consuming nearly a fifth of the nation’s economy. Meanwhile, Congress is nearing the end of the year without having finished either its annual spending bills or several other high-priority health items. Kimberly Leonard of the Washington Examiner, Joanne Kenen of Politico and Mary Agnes Carey of Kaiser Health News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk about the latest KHN-NPR “Bill of the Month.”
-
Pharma’s Take On The Pelosi Drug-Pricing Bill: Fair Warning Or Fearmongering?
The pharmaceutical industry’s argument that capping drug prices would compromise drug innovation stands “on very shaky ground.”
-
HHS Hands Out Free HIV Prevention Drugs. Do You Qualify?
Called “Ready, Set, PrEP,” the federal program will provide medication that can reduce the chances of getting AIDS to at-risk patients who don’t have insurance.
-
KHN’s ‘What The Health?’: How’s That Open Enrollment Going?
Open enrollment for the Affordable Care Act’s marketplace plans is halfway over and, so far, the number of people signing up is down, but not dramatically. Meanwhile, Congress and President Donald Trump can’t seem to agree on what to do about teen vaping, drug prices or “surprise” medical bills. And Democrats lurch to the left on abortion. Paige Winfield Cunningham of The Washington Post, Kimberly Leonard of the Washington Examiner and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news.
-
White House Unveils Finalized Health Care Price Transparency Rule
The final directive drew swift responses from the hospital and insurance industries. The Trump administration also released a proposed rule that would require health insurers to spell out for all services beforehand just how much patients may owe for their out-of-pocket costs.
-
KHN’s ‘What The Health’: Spending Bill Slowdown
It’s November, do you know where your HHS spending bill is? Still stuck in Congress. Meanwhile, lawmakers move ahead on restricting tobacco products for youth while the administration’s proposal is MIA. Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news from the week. Also, Rovner interviews Dan Weissmann, host of the podcast “An Arm and a Leg.”
-
Voters Say Congress Needs To Curb Drug Prices, But Are Lawmakers Listening?
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
-
Listen: HHS Files Challenge Over Rights To Gilead’s HIV-Prevention Drug
KHN's Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
-
Analysis: Elizabeth Warren Throws Down The Gauntlet
She has led the way, but all the candidates need to come clean about their health care proposals.
-
FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors.
-
Moved Overseas For School, Stayed For Insulin
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
-
Pharma Sells States On ‘Netflix Model’ To Wipe Out Hep C. But At What Price?
Manufacturers of lucrative drugs say they’re offering discounts off the high sticker prices ― but taxpayers footing the big bills might never know what the state is paying or if it’s getting a good deal.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
-
KHN’s ‘What The Health?’: Democrats Do Drugs (Prices)
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
-
California Governor’s Bill-Signing Marathon Offers Glimpse Of 2020 Issues
California Gov. Gavin Newsom signed off on an array of health care bills that will significantly affect the lives of Californians, including many college students, pregnant women, schoolchildren and dialysis patients.
-
California’s New Transparency Law Reveals Steep Rise In Wholesale Drug Prices
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.